Abstract A 47-year-old Caucasian man developed mild diarrhoea associated with more than 10 kg weight loss, severe fatigue and anaemia. Endoscopy demonstrated deposits of AA amyloid within the gastrointestinal tract. He had heavy proteinuria with a serum albumin of 15 g/L consistent with systemic AA amyloidosis. He had no symptoms to suggest an underlying chronic inflammatory condition but had CRP 130 mg/L and SAA 474 mg/L. In an attempt to identify the source of his inflammatory response, he underwent a contrast-enhanced whole-body computed tomography scan, which revealed a necrotising mass lesion in the right kidney consistent with a renal cell carcinoma. It also showed non-mechanical obstruction of the small bowel and, immediately post-imaging, the patient developed intractable vomiting followed by oliguric renal failure requiring haemodialysis. Despite his renal and gut failure, he underwent right radical nephrectomy without further complications. Histology showed complete resection of a clear cell renal cell carcinoma and renal amyloid deposits. Post-surgery, his acute-phase response decreased to normal, consistent with the renal cell carcinoma acting as the inflammatory stimulus. Although he remains dialysis dependent, his gut function improved and he has regained both normal weight and serum albumin. Our case demonstrates partial resolution of AA amyloidosis with removal of the inflammatory source.
Introduction
AA amyloidosis is the most serious potential complication of any chronic inflammatory condition. In the developed world, the most common underlying causes are inflammatory arthritis, particularly rheumatoid arthritis, chronic infections such as bronchiectasis and chronic sepsis complicating paraplegia or drug abuse and inflammatory bowel disease. It has also rarely been described in association with solid organ malignancy, metastatic disease and Hodgkin's lymphoma [1] [2] [3] [4] [5] [6] [7] [8] .
Although there are new exciting developments in the treatment for AA amyloidosis, the most consistent feature that has been demonstrated for better outcome is to recognise the underlying source of the inflammatory process and remove it. Our case, once again, demonstrates a favourable outcome after resection of renal cell carcinoma that was driving the systemic amyloidosis.
Case report
A previously entirely healthy 47-year-old Caucasian man developed mild diarrhoea containing mucus and blood associated with more than 10 kg weight loss, severe fatigue and anaemia over a period of 3 months. An endoscopy suggested chronic inflammation macroscopically but biopsies demonstrated deposits of AA amyloid within the stomach, duodenum and the colon (Figs. 1 and 2) . Two months later, he presented with nephrotic range proteinuria (4 g/L) with a serum albumin of 15 g/L and eGFR of 108 ml/min, consistent with systemic AA amyloidosis. I123-labelled serum amyloid protein (SAP) scan showed amyloid deposits in the liver, spleen, gut and kidneys. There was no evidence of cardiac amyloidosis on echocardiography.
He had no symptoms to suggest an underlying chronic inflammatory condition but had clear biochemical evidence of an upregulated acute-phase response with CRP 130 mg/L and SAA 474 mg/L (median level in healthy blood donors 3 mg/L). An autoantibody profile was normal and, in an attempt to identify the source of his inflammatory response, he underwent a contrast-enhanced whole-body computed tomography (CT) scan. This revealed a necrotising mass lesion in the right kidney consistent with a renal cell carcinoma without any evidence of metastases (Fig. 3) . It also showed non-mechanical obstruction of the small bowel and immediately post-imaging. The patient developed intractable vomiting followed by oliguric renal failure requiring haemodialysis. The exact cause of acute kidney injury is unclear but can possibly be down to contrast with CT, prerenal element with a background of amyloidosis and renal cell carcinoma. Given his pre-existing poor nutritional status and high metabolic requirements, he was started on total parenteral nutrition. Despite his renal and gut failure, he underwent right radical nephrectomy without further complications. Histology showed complete resection of a clear cell renal cell carcinoma and renal amyloid deposits, and it was of AA type (Figs. 4 and 5) . Post-surgery, his acute-phase response fell to the normal level, consistent with the renal cell carcinoma acting as the inflammatory stimulus. He remains dialysis dependent, although his gut function improved, and within 2 months, he no longer required nutritional support and had regained both normal weight and serum albumin of 38 g/L (Fig. 6 ).
Discussion
AA (systemic) amyloidosis involves the deposition of amyloid protein in tissues. The amyloid fibrils are derived from N-terminal cleavage fragments of the hepatic acutephase reactant serum amyloid A protein (SAA). SAA is an apolipoprotein constituent of high-density lipoprotein which is synthesised by hepatocytes under the transcriptional regulation of the proinflammatory cytokines IL-6, IL-1 and TNF-alpha. Like CRP, SAA is a highly dynamic acute-phase response protein and circulating levels can increase from a baseline of \3 mg/L to as high as 2000 mg/L. High levels are maintained throughout an inflammatory response but, after termination of the stimulus levels, fall with a half life of \24 h [9, 10] . Sustained high circulating levels of SAA are a prerequisite for the development of AA amyloidosis but are clearly not sufficient, as amyloidosis develops in \5 % of the at-risk population. The nature and role of other risk factors is not entirely clear, although SAA isotype, extracellular matrix components and macrophage factors have all been implicated. AA amyloidosis is a multisystem disease and amyloid deposits can be found in almost all sites on biopsy. Patients almost always present with proteinuric renal dysfunction. More extensive disease can produce hepatosplenomegaly and gut dysfunction, usually causing diarrhoea and weight loss. Symptomatic cardiac or nervous system amyloidosis occurs in \2 % of cases and is generally evidence of very advanced disease.
Malignancy is the underlying inflammatory driver in \7 % of AA amyloidosis. The association of amyloidosis and renal cell carcinoma was first reported by Ask-Upmark in 1940, who described 18 cases. Large autopsy series suggest that renal cell carcinoma is very much the most common solid organ malignancy to cause AA amyloidosis, accounting for 25-42 % of reported cases, but that, conversely, amyloid deposits are only seen in 2.1-3.2 % of patients who died with a renal cell carcinoma [8, 11] . Renal cell tumours are known to produce IL-6, which can act as an autocrine growth factor. High levels of tumour-derived IL-6 can result in increased circulating SAA and CRP [12] . Indeed, these acute-phase proteins have been used as tumour markers and anti-IL-6 antibodies are now undergoing phase 2/3 trials in metastatic renal cell carcinoma [13] .
There have been 20 cases of the co-existence of amyloidosis and renal cell carcinoma reported in the literature. In two cases, the amyloidosis appears to have been of type AL, complicating concomitant myeloma and, in the other cases, the amyloid was of type AA. Amyloid deposits was found to occur in various tissues at extracellular sites in the kidney, liver, spleen, adrenals and mucosa of the upper respiratory tract. Four cases of retroperitoneal amyloid deposits have also been reported. AA amyloidosis has been induced by other solid organ malignancies, gastrointestinal stromal tumours and bladder cancer. Benign neoplasms like hepatic adenoma and hyaline vascular Castleman's disease are also associated with AA amyloidosis (Table 1) .
The majority of cases presented with proteinuric renal impairment rather than direct symptoms from the tumour. A retrospective review of 68 cases has identified two main types of amyloid deposit in the kidney: glomerular and vascular. The glomerular form was mainly described as 11 Nature of amyloid deposits in hypernephroma. Immunocytochemical studies in 2 cases associated with amyloid polyneuropathy mesangial nodular or mesangiocapillary types and was associated with nephrotic range proteinuria. The vascular form was associated with lesser proteinuria. In the study, it was found that age, tubular atrophy, glomerular deposit pattern and arteriolar amyloid load were predictors of renal insufficiency. Haematuria was found in cases where glomerular amyloid load and subepithelial deposits were important. Either partial or complete remission of amyloidosis was achieved in the cases after removal of the cancer which acted as the main driver [12, 14] (Table 1) . Untreated, AA amyloidosis is a serious disease with a significant morbidity and mortality due to end-stage renal disease [1] . Patients with persistently high circulating levels of SAA are at particular risk of complications, including progression to renal failure, and of death [15, 16] (Table 2 ). In a review of 374 cases of AA amyloidosis, the mean survival time from diagnosis was 133 months, with older age, reduced serum albumin concentration and endstage renal failure at baseline, and the degree by which the SAA concentration was elevated during follow-up were poor prognostic factors [1] . Successful treatment of the underlying inflammatory process, including with surgical resection of the tumour, as demonstrated in our case, can lead to the stabilisation of or improvement in renal function, reduction in protein excretion and partial resolution of amyloid deposits [17] [18] [19] [20] [21] [22] [23] (Fig. 7) . In our patient case, the renal dysfunction appears irreversible, but we expect to see amyloid regression from the liver and spleen in time and, provided there is no evidence of tumour recurrence, the long-term management plan is renal transplantation.
Conclusion
AA amyloidosis is always a complication of an underlying chronic inflammatory state [24] . In 6 % of cases, the nature of the underlying condition is not overt at presentation [1] . In these cases, a comprehensive search for the underlying condition must be made, as effective treatment which terminates the acute-phase response will prevent further amyloid deposition and, in some cases, may permit sufficient amyloid regression to preserve renal function. Renal cell carcinoma is a rare but potentially fully resectable cause of AA amyloidosis, which is often completely asymptomatic and should be actively sought in patients of AA amyloidosis of unknown aetiology. 
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